托珠单抗联合利妥昔单抗治疗多中心型Castleman病合并激素耐药肾病综合征1例  

Tocilizumab and rituximab in the treatment of multicenter Castleman's disease with steroid-resistant nephrotic syndrome:a case report

作　　者：朱华艳 雷欣[1] 陈亮亮 陈江华 韩飞 Zhu Huayan;Lei Xin;Chen Liangliang;Chen Jianghua;Han Fei(Kidney Disease Center,the First Affiliated Hospital,Zhejiang University School of Medicine,Institute of Nephrology,Zhejiang University,Hangzhou 310003,China,Huzhou 313000,China;Nephrology Department of Huzhou First People's Hospital,Huzhou 313000,China)

机构地区：[1]浙江大学医学院附属第一医院肾脏病中心,浙江大学肾脏病研究所,杭州310003,湖州313000 [2]湖州市第一人民医院肾内科,湖州313000

出　　处：《中华肾脏病杂志》2024年第9期749-752,共4页Chinese Journal of Nephrology

摘　　要：该文报道1例罕见的以肾病综合征为首发表现的特发性多中心型Castleman病病例。患者男性,68岁,以水肿起病,临床表现为肾病综合征,伴多发淋巴结肿大,肾活检病理表现符合肾小球微小病变改变,颈部淋巴结活检符合Castleman病。通过糖皮质激素联合托珠单抗、后加用利妥昔单抗治疗,随访14个月肾病综合征达到缓解状态。The paper reports a rare case of idiopathic multicentric Castleman's disease with nephrotic syndrome as the first presentation.The patient was a 68-year-old male,presented with edema at admission.His clinical manifestations included nephrotic syndrome,and multiple enlarged lymph nodes.Renal biopsy showed minimal change disease,and cervical lymph node biopsy showed Castleman's disease.The patient received treatment of glucocorticoid combined with tocilizumab,and then rituximab.After 14 months of follow-up,the patient achieved remission of nephrotic syndrome.

关 键 词：CASTLEMAN病 肾病综合征 利妥昔单抗 托珠单抗 

分 类 号：R692[医药卫生—泌尿科学]